

REPLACED BY  
ART 34 AMDT

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

RECD 01 NOV 2004



WIPO PCT

Applicant's or agent's file reference FP/FC-PCT Frebourg	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA416)	
International application No. PCT/EP 03/08476	International filing date (day/month/year) 18.07.2003	Priority date (day/month/year) 19.07.2002
International Patent Classification (IPC) or both national classification and IPC C12Q1/68		
Applicant INSERM et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.  
  
☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 16 sheets.

3. This report contains indications relating to the following items: ---
- 29.11.2004
- EPO-531
- I ☒ Basis of the opinion
  - II ☐ Priority
  - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV ☐ Lack of unity of invention
  - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI ☐ Certain documents cited
  - VII ☐ Certain defects in the international application
  - VIII ☐ Certain observations on the international application

Date of submission of the demand  12.02.2004	Date of completion of this report  29.10.2004
Name and mailing address of the International preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer  Luzzatto, E  Telephone No. +49 89 2399-8169 

REPLACED BY  
ART 34 AMBET

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/08476**

**I. Basis of the report**

1. With regard to the elements of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17):*

**Description, Pages**

1-77 as originally filed

**Claims, Numbers**

1-40 received on 12.02.2004 with letter of 11.02.2004

**Drawings, Sheets**

1/9-9/9 as originally filed

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.  
☒ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☒ the claims, Nos.: 41-43  
☐ the drawings, sheets:

REPLACED BY  
ART 34 AMDT

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/08476**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims	1-40
	No: Claims	
Inventive step (IS)	Yes: Claims	1-40
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-40
	No: Claims	

**2. Citations and explanations**

**see separate sheet**

### PART III

The IPEA agrees with the clarity objections (Art. 6 PCT) raised in the Search Report by the ISA against original claims 1, 19, 20, 24, 25, 26, 28-42 (which substantially correspond to present claims 9 (cl. 1), 22 (cl. 25-26), 24-39 (cl. 28-42)). Original claims 19, 20 and 24 have been deleted.

The objection against present cl. 9 has been overcome; the present claim is in line with the subject-matter of original claim 1 which has been searched. Claim 9, therefore, will be examined in full.

In view of the deletion of original claim 19, the same applies to claims 24-39, which had been searched disregarding their direct or indirect dependency on original claim 19.

On the other hand, cl. 22 (original claims 25 and 26) will only be examined insofar as relating to subject-matter for which the search has been carried out, namely not taking into account the 3rd feature listed therein.

### PART V

#### NOVELTY

- 1) Claim 22 is novel in view of the Applicant's argument that the decamer disclosed in D3 does not satisfy the requirement that the free energy of formation of the 100% matched duplex does not exceed 11 kcal/mol. (see however item 8 hereinbelow)
- 2) With respect to the issue of novelty of a product claim, it is irrelevant whether the product disclosed in the prior art has been obtained following a certain method or not: what is essential is to determine whether the said product comprises all of the features of the claimed one; if the answer is "it does", then the claim to that product lacks novelty.  
However, none of the available documents discloses sets of primers meeting all the criteria listed in claim 9. In particular, D1 (WO-A-9958721) discloses in general sets of primers suitable for multiplex amplification reactions wherein: a) the sense and antisense primers comprise a hybridisation segment and a constant segment (the nucleotide tag of the present application), b) all sense primers comprise the same constant segment and c) all antisense primers comprise the same constant segment, the sense and antisense constant segments differing from each other

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/08476

(see p. 3, l. 10-p. 7, l. 12). The constant segments may have a length of between 15 and 35 base pairs and should not hybridise to other constant segments, to the target or to the hybridisation segments (p. 15, l. 19-34). The primers are selected on the basis of the required characteristics, such as melting temperature, using for instance available computer programs (p. 16, l. 8-36). The primers can be packaged in a kit (p. 26, l. 9-22, claims 27,28). It is however silent as to any deltaG-linked parameter. Thus, it cannot take away the novelty of the method claims based on such a feature (see hereinbelow). The novelty of product claim 9 could be destroyed by D1 if this document disclosed sets of chimeric primers which could be shown (by calculation) to meet the aforementioned deltaG parameter. However, D1 only discloses a pair of constant segments (corresponding to the "nucleotide tag" to which the present application relates, SEQ ID NO: 1 and 2) and **no concrete chimeric primer**. Hence, although it could be likely that among the primers used in the examples of D1 (see in particular ex. 5 where 558 different targets are simultaneously amplified) some of them fall within the scope of claim 9, in view of the absence of any indication as to their actual sequence and as to any role for deltaG, it has to be concluded that D1 does not prejudice the novelty of claim 9.

Hence, claims 9 as well as claims 11, 15-18, 26-28, 40 depending directly or indirectly thereon are novel (Art. 33(2) PCT).

- 4) Method claims 1-8, 19-20, 29-39 are novel, because none of the available documents discloses a method as that of claims 1 or 2, or 29-39.
- 5) Claims 12-14, 21, 23-25 are novel since the sequences to which they relate are not disclosed by any of the available documents.

**INVENTIVE STEP**

- 6) Claims 1, 2, 19 and 20 involve an inventive step (Art. 33(3) PCT). The closest prior art is represented by D1 (see also item 2 hereinabove), which discloses a method for the selection of primers based on characteristics such as length or melting temperature (p.16, l. 8-36).  
Starting from this document, the technical problem underlying the said claims may be defined as that of providing an alternative method for the selection of primers comprising a hybridisation segment and a tag suitable for multiplex PCR.  
None of the available documents suggests using the parameters to which present

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/08476

claims 1,2, 19 and 20 relate. Hence, and in view of the results shown in the application (see examples) an inventive step for the subject-matter of claims 1 and 2 is to be acknowledged.

The same applies to claims 3-8 dependent thereon, to claims 9-11 which relate to a plurality of primer pairs, to claims 12-14 which relate to novel primers obtained by the said method, to claims 15-18 dependent on claims 9-14, to claims 21-25, relating to tags obtained by the said method (as to claim 22, however, see item 8 hereinbelow), to claims 29-39 relating to methods using the novel and inventive primer pairs and to claim 40 relating to a kit comprising them.

**Further remarks**

- 8) Claim 22 lacks clarity (Art. 6 PCT) because its scope is only defined by circumstances external to the claim: whether a "nucleotide tag" falls or not within the scope of the claim depends entirely on the composition of the target nucleic acid or mixture.
- 9) Claim 40 lacks clarity and conciseness (Art. 6 PCT) in view of the huge number of possible alternatives it encompasses ("...and/or..."; "...optionally...") (see also the PCT Guidelines for Search and Examination, 5.18, 5.40).
- 10) Claim 1 relates to a specific software; with respect to the clarity of the term (Art. 6 PCT), it has to be noted that the software may not be available for the whole of the required time and that it could change in the course of time. Hence, the arguments set out in the Guidelines for Search and Preliminary Examination as to trademarks (5.39) fully apply to the present case. The Applicant should thus have removed this reference to a specific software from the claim.

CLAIMS

1. Method for producing a plurality of pairs of sense and antisense composite primers, said plurality being  
5 specially adapted to the quantitative multiplex amplification of a plurality of target nucleotide sequences present in a nucleic acid or a mixture of nucleic acids, wherein each one of said sense or antisense composite primers produced consists:
- 10
- of a hybridization segment, respectively sense or antisense, which pairs with said nucleic acid or mixture of nucleic acids, so as to constitute a sense or antisense primer for one of the target  
15 nucleotide sequences of the plurality targeted, and
  - of a nucleotide tag which is attached to the 5' end of said hybridization segment, but which does not pair with said nucleic acid or mixture of  
20 nucleic acids,
  - and, optionally, of a non-nucleotide component, characterized in that the respective sequences of the sense and antisense composite primers of said plurality of pairs are selected such that:
- 25
- a) each sense composite primer has, within said plurality, an antisense composite primer with which it forms a pair of sense and antisense composite primers whose respective hybridization  
30 segments constitute, with respect to one another, a pair of sense and antisense primers for one of said target nucleotide sequences, each one of said target nucleotide sequences of the plurality targeted thus having a pair of sense and antisense composite primers which is intended for its  
35 amplification,
  - b) all the sense composite primers contain the same nucleotide tag and all the antisense composite primers contain the same nucleotide tag, the tag

- of the sense composite primers being different from that of the antisense composite primers,
- c) the sequence of the tag of the sense composite primers is absent from said nucleic acid or mixture of nucleic acids, or, at the very least, is only present therein at a frequency at least two times less than that predicted statistically for a random sequence of the same length, and the sequence of the tag of the antisense composite primers is absent from said nucleic acid or mixture of nucleic acids, or, at the very least, is only present therein at a frequency at least two times less than that predicted statistically for a random sequence of the same length,
- d) the melting temperature of each composite primer (whether it is a sense or antisense primer) has a value 10 to 15°C higher (limits inclusive) than that which its hybridization segment would exhibit when naked without tag,
- e) each composite primer of said plurality of pairs has a sequence such that no composite primer of said plurality of pairs can form, with itself or with another composite primer of the same plurality, complete or partial base pairing for which the variation in free energy  $\Delta G$  associated with the formation of this possible pairing would be greater than 14 kcal/mol, said variation in free energy  $\Delta G$  being calculated using the "Primer Premier" software version 5.0 marketed by PREMIER Biosoft International,
- and in that the thus selected plurality of antisense composite primer pairs is synthesized.

2. Plurality of pairs of sense and antisense composite primers specially adapted to the quantitative multiplex amplification of a plurality of target nucleotide sequences present in a nucleic acid or a mixture of nucleic acids, characterized in that it is obtainable using the method according to Claim 1.



3. Plurality of pairs of sense and antisense composite primers according to Claim 2, characterized in that said nucleic acid or mixture of nucleic acids  
5 is derived from mammalian cells.

4. Plurality of pairs of sense and antisense composite primers according to either one of Claims 2 and 3, characterized in that said nucleic acid or  
10 mixture of nucleic acids is derived from human cells.

5. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 4, characterized in that said nucleic acid or mixture  
15 of nucleic acids corresponds to the total genomic DNA of an organism or of a microorganism.

6. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 4, characterized in that said nucleic acid or mixture of  
20 nucleic acids corresponds to complementary DNA produced *in vitro* from RNA of an organism or of a microorganism.

7. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 6, characterized in that the tag of the sense composite primers, and also that of the antisense composite primers, each comprise, independently of one another, from 8 to 18 nucleotides, preferentially from 8 to 15  
25 nucleotides, more preferentially 8 to 14 nucleotides, even more preferentially 9 to 12 nucleotides, very preferentially 10 nucleotides.  
30

8. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 7, characterized in that the sequence of the tag of the sense composite primers, and also that of the tag of the antisense composite primers, each consist of a chain of 10 nucleotides the GC content of which is  
35

between 20% and 60% (limits inclusive), preferentially between 20% and 50% (limits inclusive), very preferentially a GC content of 40%.

5 9. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 8, characterized in that the tag of the sense composite primers and/or that of the antisense composite primers is/are selected from the group consisting of the  
10 sequence of SEQ ID NO:1, the sequence of SEQ ID NO:2, and the sequences complementary thereto, SEQ ID NO:47 and SEQ ID NO:48.

10. Plurality of pairs of sense and antisense  
15 composite primers according to any one of Claims 2 to 9, characterized in that it comprises at least one pair of sense and antisense composite primers the respective sense and antisense hybridization segments of which have the following sequences:

- 20 - the sequences of SEQ ID NO:3 and SEQ ID NO:4, or  
- the sequences of SEQ ID NO:7 and SEQ ID NO:8, or  
- the sequences of SEQ ID NO:9 and SEQ ID NO:10,  
or  
- the sequences of SEQ ID NO:11 and SEQ ID NO:12,  
25 or  
- the sequences of SEQ ID NO:13 and SEQ ID NO:14.

11. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to  
30 9, characterized in that it comprises at least one pair of sense and antisense composite primers the respective sense and antisense hybridization segments of which have the following sequences:

- 35 - SEQ ID NO:27 and SEQ ID NO:28, or  
- SEQ ID NO:29 and SEQ ID NO:30, or  
- SEQ ID NO:31 and SEQ ID NO:32, or  
- SEQ ID NO:33 and SEQ ID NO:34, or  
- SEQ ID NO:35 and SEQ ID NO:36.

12. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 11, characterized in that the composite primers of said plurality of pairs each have a hybridization segment the melting temperature  $T_m$  of which is between 50 and 65°C, preferentially between 58 and 62°C, all limits inclusive.

13. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 12, characterized in that the composite primers of said plurality of pairs each have a melting temperature  $T_m$  of greater than 65°C, preferentially of between 68°C and 72°C, all limits inclusive.

14. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 13, characterized in that said non-nucleotide component is a label for detecting nucleotide products.

15. Plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 14, characterized in that it comprises from 2 to 15 pairs of sense and antisense composite primers.

16. Method for producing a plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 15, characterized in that it comprises the following steps:

- a) selected from:
- pairs of sense and antisense hybridization segments which each form a pair of sense and antisense primers for one of said target nucleotide sequences, and
  - nucleotide tags which are absent from said nucleic acid or mixture of nucleic acids, or which at the very least are only present therein at a frequency at least

two times less than that predicted statistically for a random sequence of the same length,

are a plurality of pairs of sense and antisense hybridization segments which covers the plurality of target nucleotide sequences targeted, and a pair of nucleotide tags, the respective sequences of which are such that:

10 when one of the two selected tags is attached to the 5' end of each selected sense hybridization segment, and the other of the two selected tags is attached to the 5' end of each selected antisense hybridization segment, then:

15

- each resulting sense or antisense composite primer has a melting temperature  $T_m$  with a value 10 to 15°C greater (limits inclusive) than that which its hybridization segment would exhibit when naked without

20 tag, and

- each resulting sense or antisense composite primer has a sequence such that it cannot form, with itself or with another resulting composite primer, a complete or partial base pairing for which the variation in free energy  $\Delta G$  associated with the formation of this pairing would be greater than 14 kcal/mol,

b) the plurality of pairs of sense and antisense composite primers which results from the selection of the plurality of pairs of hybridization segments and of the pair of tags made in step a), and of the addition of the sequence of one of the two selected tags to the 5' end of each sense hybridization segment of the selected plurality, and of the addition of the sequence of the other of the two selected tags to the 5' end of each antisense hybridization segment of the selected plurality, is produced.

17. Method for producing a plurality of pairs of composite primers according to any one of Claims 2 to 15, characterized in that it comprises the following steps:

5

a) a plurality of pairs of sense and antisense hybridization segments is selected:

- in which each pair of segments constitutes a pair of sense and antisense primers for each one of the target nucleotide sequences targeted, and
- in which no segment can form, with itself or with another segment of this plurality, a complete or partial base pairing for which the variation in free energy  $\Delta G$  associated with the formation of this possible pairing would be greater than 14 kcal/mol, preferentially 13 kcal/mol, more preferentially 12 kcal/mol,

- b) two nucleotide tags are selected:
  - the respective sequences of which are absent from said nucleic acid or mixture of nucleic acids, or at the very least which are only present therein at a frequency at least two times less than that predicted statistically for a random sequence of the same length,

25

- which have respective sequences such that their addition, for one, to the 5' end of each one of the sense hybridization segments selected in step a) and, for the other, to the 5' end of each one of the antisense hybridization segments selected in step a), does not produce a set of sense and antisense composite primers within which a composite primer would be capable of forming, with itself or with another composite primer of this set, a complete or partial base pairing, the formation of which would correspond to a variation in free energy  $\Delta G$  of greater than 14 kcal/mol,

35

c) a plurality of pairs of sense and antisense composite primers is produced by adding the sequence of one of the two tags selected in step b) to the 5' end of each sense hybridization segment selected in step a), and by adding the sequence of the other of the two tags selected in step b) to the 5' end of each antisense hybridization segment selected in step a), whereby a plurality of pairs of composite primers according to any one of Claims 2 to 15 is produced.

10

18. Method according to Claim 17, characterized in that said hybridization segments, whether they are sense or antisense, each have (in the absence of a tag) a melting temperature  $T_m$  of between 50 and 65°C (limits inclusive).

15

19. Plurality of pairs of composite primers according to any one of Claims 2 to 15, characterized in that it can be obtained using a method according to any one of Claims 16 to 18.

20

20. Pair of sense and antisense composite primers suitable for use within a plurality according to any one of Claims 2 to 15, characterized in that it is selected from a plurality according to Claim 19.

25

21. Method for producing a pair of tags suitable for use as a tag of sense composite primers and a tag of antisense composite primers in a plurality of pairs of sense and antisense composite primers according to any one of Claims 2 to 15 and 19, which pair is termed universal, characterized in that it comprises the following steps:

30

a) at least 30 pairs of sense and antisense hybridization segments are selected:

35

- which each form a pair of sense and antisense primers for a nucleotide target, so as to target at least 30 different nucleotide targets on said nucleic

acid or mixture of nucleic acids, and taking care that these at least 30 targets exhibit a uniform distribution throughout the length of said nucleic acid or mixture of nucleic acids, or at the very least in  
5 the region(s) in which are found the target nucleotide sequences whose amplification in multiplex is desired, and

- each segment of which has a melting temperature  $T_m$  of between 50 and 65°C (limits inclusive),  
10 thus constituting a set of pairs of test sense and antisense segments,

b) for each pair of test segments of the set, the maximum value of the variation in free energy  $\Delta G$  that  
15 this pair can exhibit, by partial or complete base pairing of each one of the two segments with itself or with the other segment of the same pair, is determined,

c) two tags of different sequences are selected:  
20 - which are not present in said nucleic acid or mixture of nucleic acids, or at the very least which are only present therein at a frequency at least two times less than that predicted statistically for a random sequence of the same length, and

25 - the addition of which, for one, to the 5' end of each test sense segment and, for the other, to the 5' end of each test antisense segment, leads to an increase of a value of between 10 and 15°C (limits inclusive) in the melting temperature  $T_m$  of each one of  
30 the test segments, and

- the addition of which, for one, to the 5' end of each test sense segment and, for the other, to the 5' end of each test antisense segment, does not for any of the pairs of test sense and antisense segments lead  
35 to an increase of more than 3 kcal/mol in said maximum value  $\Delta G$  determined for each test pair in step b),

d) the two selected tags are produced.

REPLACED BY  
ART 34 AMOT

22. Pair of nucleotide tags intended to cooperate with a plurality of sense and antisense hybridization segments so as to form a plurality of pairs of sense or antisense composite primers according to any one of  
5 Claims 2 to 15 and 19, which pair is termed universal, characterized in that it is obtainable by the method according to Claim 21.

23. Pair of nucleotide tags according to Claim 22,  
10 characterized in that it is selected from the group of pairs of tags of respective sequences:

- the sequences SEQ ID NO:1 and SEQ ID NO:2,
- the sequence SEQ ID NO:1 and the sequence complementary to SEQ ID NO:2 (SEQ ID NO:48),
- 15 - the sequence complementary to SEQ ID NO:1 (SEQ ID NO:47) and the sequence SEQ ID NO:2,
- the sequence complementary to SEQ ID NO:1 (SEQ ID NO:47) and the sequence complementary to SEQ ID NO:2 (SEQ ID NO:48).

20

24. Nucleotide tag suitable for use as a tag in the sense composite primers or in the antisense composite primers of a plurality according to any one of Claims 2 to 15 and 19, characterized in that it is selected from  
25 a pair of tags according to Claim 22 or 23.

25. Nucleotide tag suitable for use as a tag in the sense composite primers or in the antisense composite primers of a plurality according to any one of Claims 2  
30 to 15 and 19, characterized in that its sequence:

- consists of 10 nucleotides,
- has a GC content of between 20% and 60% (limits inclusive), preferentially between 20% and 50% (limits inclusive), very preferentially a GC content of 40%,  
35 and
- is absent from said nucleic acid or mixture of nucleic acids, or at the very most is only present therein at a frequency at least two times less than



that statistically predicted for a random sequence of the same length.

26. Nucleotide tag according to Claim 25,  
5 characterized in that, in addition, its sequence is such that the complete pairing with the chain of 10 nucleotides which constitutes the sequence completely complementary thereto exhibits a free energy of formation  $\Delta G$  which does not exceed 11 kcal/mol.

10

27. Tag according to either one of Claims 25 and 26, characterized in that its sequence is selected from the group consisting of the sequence of SEQ ID NO:1, the sequence of SEQ ID NO:2, and the sequences  
15 complementary thereto, SEQ ID NO:47 and SEQ ID NO:48.

28. Sense or antisense composite primer suitable for use within a plurality according to any one of Claims 2 to 15, characterized in that it is selected from a pair  
20 of primers according to Claim 20, and in that the tag which it contains is a tag according to any one of Claims 24 to 27.

29. Method for amplifying in multiplex a plurality of  
25 target nucleotide sequences present in a nucleic acid or a mixture of nucleic acids, by hybridizations and elongations of a plurality of pairs of amplification primers, characterized in that said plurality of pairs of amplification primers is a plurality of pairs of  
30 sense and antisense composite primers according to any one of Claims 2 to 15 and 19.

30. Method of amplification according to Claim 29, characterized in that said plurality of target  
35 nucleotide sequences amplified in multiplex consists of 2 to 16 target sequences.

31. Method of amplification according to Claim 29 or 30, characterized in that said target nucleotide

sequences consist of 90 to 500 bp, preferentially of 90 to 300 bp.

32. Method for the quantitative multiplex  
5 amplification of a plurality of target nucleotide  
sequences present in a nucleic acid or a mixture of  
nucleic acids, by hybridizations and elongations of a  
plurality of pairs of amplification primers,  
characterized in that the method according to any one  
10 of Claims 29 to 31 is used, carrying out said  
hybridizations and/or elongations in the presence of an  
agent which facilitates DNA strand separation, such as  
dimethyl sulphoxide (DMSO) or triethylammonium acetate  
(TEAA).

15

33. Method of amplification according to Claim 32,  
characterized in that said hybridizations and  
elongations are carried out with successive  
hybridization-elongation-denaturation cycles until the  
20 amplifications of said target nucleotide sequences have  
exponential phase kinetics.

34. Method of amplification according to either one of  
Claims 32 and 33, characterized in that all the pairs  
25 of composite primers are used in equimolar  
concentration.

35. Method for determining the presence or absence of  
at least one genomic rearrangement within a genetic  
30 material B relative to a reference genetic material A,  
characterized in that:

- at least one nucleotide target which  
constitutes a marker for the rearrangement(s) sought is  
selected, and in that

35 - the method of amplification according to any  
one of Claims 29 to 31, or else that according to any  
one of Claims 32 to 34, is applied to said genetic  
material B, using, for each target selected, a pair of  
composite primers which is selected from a plurality of

pairs of composite primers according to any one of Claims 2 to 15 and 19, and which is suitable for the amplification of this target from the genetic material B,

- 5 said material B being considered as exhibiting said genetic rearrangement when the result of amplification of said at least one marker target, obtained from the material B, is significantly different from that which is obtained from the reference material A under  
10 identical conditions, and  
said material B being considered as not exhibiting said genetic rearrangement when the result of amplification of said at least one marker target, obtained from the material B, is not significantly different from that  
15 which is obtained from the reference material A under identical conditions.

36. Method according to Claim 35, characterized in that said at least one genomic rearrangement is a gene  
20 rearrangement.

37. Method according to Claim 35, characterized in that said at least one genomic rearrangement is a chromosomal rearrangement.

25 38. Method according to any one of Claims 35 to 37, characterized in that said genetic material B comprises at least one human gene.

30 39. Method for determining at least one of the limits of one or more genomic rearrangement(s) which has (have) been detected within a genetic material B by comparison with a reference genetic material A, characterized in that:

- 35 a) a candidate region within which said at least one limit is potentially located is selected,  
b) for each rearrangement, a set of nucleotide targets is chosen, among which at least one is chosen to constitute a marker for this rearrangement, the

other target(s) being chosen on both sides or on one or other sides of this marker target inside the candidate region chosen in step a) so as to cover the extent of this candidate region,

5           c) the method according to any one of Claims 29 to 31, or else the method according to any one of Claims 32 to 34, is applied to said genetic material B, using, for each target of said chosen set, at least one pair of composite primers which is chosen from a plurality  
10 of pairs of composite primers according to any one of Claims 2 to 15 and 19, and which is suitable for amplifying this target from said genetic material A,

          d) for each target, the intensity of amplification thus obtained from said genetic material B is measured,  
15 and it is compared to the control intensity which is obtained for this same target under the same conditions but by applying said method of amplification to said reference genetic material A,

          e) it is determined whether, within the chosen set  
20 of targets, at least one target is amplified with an intensity not significantly different from the control intensity, and, if this is not the case, steps a) to e) are repeated while broadening the candidate region chosen in step a),

25 said at least one limit of the or of each one of the rearrangements within said genetic material B being considered to be within a zone between:

- the position of the marker target for said rearrangement, and

30           - the position of the target which has been amplified with an intensity not significantly different from the control intensity or, if there are several of them, with that which is closest to said marker target,

          f) if desired, the precision of determination of  
35 said limit is refined, by gradually walking into the zone determined in step e) above, by repeating steps a) to e), choosing as candidate region in step a) the zone identified in the immediately preceding step e), and

choosing in step b) a set of nucleotide targets which covers this zone identified in step e).

40. Method for producing a genomic rearrangement map, characterized in that the limits of at least one genomic rearrangement are determined using the method according to Claim 39, and in that these limits are recorded on a gene or chromosome map.

41. Method for identifying, and optionally isolating, at least one gene liable to be involved in a genetic disease, characterized in that:

- the method for determining the presence or absence of at least one genomic rearrangement according to any one of Claims 35 to 38 is carried out on a genetic material B derived from organisms exhibiting said genetic disease, a genomic material which is comparable but derived from control organisms serving as reference genomic material A, so as to detect the rearrangement(s) present in the material B relative to the material A, and in that

- the gene(s) affected by the detected rearrangement(s) is (are) identified, and optionally isolated,  
this (these) identified and optionally isolated gene(s) corresponding to the gene(s) liable to be involved in said genetic disease.

42. Method for diagnosing a genetic disease from which an individual might suffer, or for estimating a propensity for this individual to develop such a disease, characterized in that the method for determining the presence or absence of at least one genomic rearrangement according to any one of Claims 35 to 38 is carried out on a sample of genetic material representative of said genetic disease, and in that said diagnosis is considered to be positive, or, where appropriate, said propensity is considered to be high, when said at least one genetic rearrangement is

determined as being present in said sample and, conversely, said diagnosis is considered to be negative, or, where appropriate, said propensity is considered to be low, 5 when said at least one genomic rearrangement is determined as being absent from said sample.

43. Kit for carrying out a method of amplification according to any one of Claims 29 to 31, and/or a 10 method of amplification according to any one of Claims 32 to 34, and/or a method for determining the presence or absence of at least one genomic rearrangement according to any one of Claims 35 to 38, and/or a 15 method for determining the limits of one or more genetic rearrangement(s) according to Claim 39, and/or a method for identifying at least one gene involved in a genetic disease according to Claim 41, and/or a diagnostic or prognostic method according to Claim 42, characterized in that it comprises at least one pair of 20 composite primers according to Claim 20, and/or at least one composite primer according to Claim 28, and/or at least one tag according to any one of Claims 24 to 27, optionally combined with an amplification primer and/or with a label for detecting nucleotide 25 products.